Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| 1 |
Lam Research
LRCX
|
$792M |
| 2 |
Johnson & Johnson
JNJ
|
$659M |
| 3 |
Datadog
DDOG
|
$571M |
| 4 |
Amazon
AMZN
|
$474M |
| 5 |
Broadcom
AVGO
|
$458M |
Top Sells
| 1 |
Workday
WDAY
|
$1.23B |
| 2 |
AbbVie
ABBV
|
$1.03B |
| 3 |
Advanced Micro Devices
AMD
|
$686M |
| 4 |
Honeywell
HON
|
$673M |
| 5 |
Amgen
AMGN
|
$620M |
Sector Composition
| 1 | Technology | 34.72% |
| 2 | Healthcare | 17.58% |
| 3 | Consumer Discretionary | 10.69% |
| 4 | Financials | 10.22% |
| 5 | Communication Services | 9.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
526
Innodata
INOD
$1.52B
| $25.8M | 0.01% |
652,860
-127,376
| -16% | -$5.03M |
|
527
Envista
NVST
$3.51B
| $25.8M | 0.01% |
1,335,972
-33,838
| -2% | -$653K |
|
528
Pfizer
PFE
$140B
| $25.4M | 0.01% |
958,315
+427,886
| +81% | +$11.4M |
|
529
RenaissanceRe
RNR
$11.3B
| $25.2M | 0.01% |
101,172
-11,830
| -10% | -$2.94M |
|
|
SEPN
530
Septerna, Inc. Common Stock
SEPN
$654M
| $25.1M | 0.01% |
+1,096,302
| New | +$25.1M |
|
531
Atlassian
TEAM
$45.3B
| $25M | 0.01% |
102,531
+86,981
| +559% | +$21.2M |
|
532
Larimar Therapeutics
LRMR
$336M
| $24.9M | 0.01% |
6,443,286
+876,431
| +16% | +$3.39M |
|
533
BlackLine
BL
$3.37B
| $24.4M | 0.01% |
402,039
+151
| +0% | +$9.18K |
|
534
Tyra Biosciences
TYRA
$646M
| $24.3M | 0.01% |
1,746,320
+679,124
| +64% | +$9.45M |
|
535
Xometry
XMTR
$2.63B
| $24.2M | 0.01% |
567,632
-88,207
| -13% | -$3.76M |
|
536
Black Hills Corp
BKH
$4.26B
| $24.2M | 0.01% |
413,447
+2
| +0% | +$117 |
|
537
Unum
UNM
$12.6B
| $24.1M | 0.01% |
330,081
+195,947
| +146% | +$14.3M |
|
538
Franklin FTSE Japan ETF
FLJP
$2.39B
| $24M | 0.01% |
840,222
-39,364
| -4% | -$1.13M |
|
539
AAR Corp
AIR
$2.69B
| $23.9M | 0.01% |
389,313
+39,505
| +11% | +$2.42M |
|
540
Dianthus Therapeutics
DNTH
$1.02B
| $23.6M | 0.01% |
1,085,648
+136,314
| +14% | +$2.96M |
|
541
Chubb
CB
$111B
| $23.5M | 0.01% |
85,112
+15,127
| +22% | +$4.18M |
|
542
Paychex
PAYX
$48.7B
| $23.5M | 0.01% |
167,476
-93,114
| -36% | -$13.1M |
|
543
Lamb Weston
LW
$8.02B
| $23.5M | 0.01% |
351,364
+28,508
| +9% | +$1.91M |
|
544
Monopar Therapeutics
MNPR
$256M
| $23.4M | 0.01% |
+1,046,899
| New | +$23.4M |
|
545
Workiva
WK
$4.56B
| $23.4M | 0.01% |
213,908
+77
| +0% | +$8.43K |
|
546
McCormick & Company Non-Voting
MKC
$18.8B
| $23.2M | 0.01% |
304,191
-6,868
| -2% | -$524K |
|
547
Medpace
MEDP
$13.8B
| $23M | 0.01% |
69,207
+25,089
| +57% | +$8.34M |
|
548
Kornit Digital
KRNT
$680M
| $22.9M | 0.01% |
740,069
-13,407
| -2% | -$415K |
|
549
Caterpillar
CAT
$198B
| $22.8M | 0.01% |
62,791
-1,030
| -2% | -$374K |
|
550
AvidXchange
AVDX
$2.06B
| $22.7M | 0.01% |
2,199,833
-242,460
| -10% | -$2.51M |
|